OBSOLETE: Suprabasal epidermolysis bullosa simplex

Suprabasal epidermolysis bullosa simplex (suprabasal EBS) is an obsolete clinical grouping that was previously used to classify a subset of epidermolysis bullosa simplex subtypes in which skin blistering occurs due to disruption within the suprabasal layers of the epidermis, rather than in the basal keratinocyte layer as seen in classical EBS forms. This category historically encompassed several rare conditions including EBS superficialis, acral peeling skin syndrome, and skin fragility-ectodermal dysplasia syndrome, among others. The suprabasal forms are caused by mutations in genes encoding proteins critical for cell-cell adhesion in the upper epidermis, such as plakophilin-1 (PKP1), desmoplakin (DSP), plakoglobin (JUP), and transglutaminase 5 (TGM5). Affected individuals typically present with skin fragility, blistering, and erosions that may be generalized or localized, often appearing at birth or in early childhood. Because this was a grouping term rather than a single disease entity, the clinical features varied depending on the specific underlying condition. Some subtypes involved additional ectodermal features such as nail dystrophy, hair abnormalities, or palmoplantar keratoderma. The term has been rendered obsolete by updated classification systems for epidermolysis bullosa, which now categorize these conditions individually based on their specific molecular defects and clinical presentations. Patients previously classified under this umbrella term are now diagnosed with their specific subtype. Treatment remains supportive and symptomatic, focusing on wound care, blister management, infection prevention, and protection of the skin from mechanical trauma. No curative therapies are currently available, though gene therapy and protein replacement strategies are under investigation for various forms of EB.

Common questions about OBSOLETE: Suprabasal epidermolysis bullosa simplex